COVID-19 Vaccine Could Be Ready By October 2020, Says Head of Pfizer

COVID-19 Vaccine Could Be Ready By October 2020, Says Head of Pfizer

With every passing day, COVID-19 looks like it won’t go away and we will have to learn to live with this coronavirus.

And this is only making us desperately wait for a vaccine, to bring our lives back to normal. While there are some vaccines that show promise, others, haven’t been so successful.

However, now, CEO of American pharmaceutical company Pfizer has stated that we won’t have to wait for long, according to a report by The Times of Israel.

Albery Bourla in an interview said, “If things go well, and the stars are aligned, we will have enough evidence of safety and efficacy so that we can… have a vaccine around the end of October.”

In case you didn’t know, Pfizer is currently developing a vaccine with German pharmaceutical giant BioNTech on a number of vaccines in Europe and the US.

Their current vaccine that goes by the name ‘BNT162’ is undergoing tests on humans after it received required clinical approvals. The company is testing four of its RNA-based vaccines to find out the most effective and safe one among the lot.

Pfizer Coronavirus Vaccine

Pfizer’s vaccine isn’t the only one that is promised to arrive at the shelves this year. The report also revealed UK pharmaceutical giant AstraZeneca’s head, Pascal Soriot has stated that one or more COVID-19 vaccines could soon start rolling out by the end of 2020.

AstraZeneca has teamed up with the University of Oxford and developed a vaccine based on a weakened strain of adenovirus.

They’ve combined Adenoviruses that cause common cold in chimpanzees with the genetic material of the novel coronavirus.

However, leading the vaccine race as of now is the US-biotech company Moderna Inc. It has even cleared stage-1 of its clinical trials last week and is all set to begin phase 2 of its trials on 600 healthy individuals.

The vaccine has shown success in producing antibodies against the novel coronavirus.

 

Source:- indiatimes

Share: